A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Beata HolkovaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; Correspondence[email protected]

Victor YazbeckMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA;

Maciej KmieciakMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Prithviraj BoseMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Shuo MaDivision of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA;

Amy KimballMarlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA;

Mary Beth TombesMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Ellen ShraderMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Wen WanDepartment of Statistics, Virginia Commonwealth University, Richmond, VA, USA;

Caryn Weir-WigginsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Amanda SinghMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Kevin T. HoganMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Sarah ConineMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Heidi SankalaMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

John D. RobertsMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA;

Thomas C. SheaDepartment of Hematology/Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA;

Steven GrantMassey Cancer Center, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA, USA; ;Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA; ;The Institute for Molecular Medicine, Virginia Commonwealth University, Richmond, VA, USA

show all

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Articles from other publishers (12)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Citations (13)

Read on this site (1)

Articles from other publishers (12)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date